IL144558A0 - Methods for identifying, treating of monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer - Google Patents

Methods for identifying, treating of monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer

Info

Publication number
IL144558A0
IL144558A0 IL14455800A IL14455800A IL144558A0 IL 144558 A0 IL144558 A0 IL 144558A0 IL 14455800 A IL14455800 A IL 14455800A IL 14455800 A IL14455800 A IL 14455800A IL 144558 A0 IL144558 A0 IL 144558A0
Authority
IL
Israel
Prior art keywords
methods
treating
identifying
breast cancer
therapeutic treatment
Prior art date
Application number
IL14455800A
Other languages
English (en)
Original Assignee
Pro Duct Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Duct Health Inc filed Critical Pro Duct Health Inc
Publication of IL144558A0 publication Critical patent/IL144558A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
IL14455800A 1999-01-26 2000-01-25 Methods for identifying, treating of monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer IL144558A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11728199P 1999-01-26 1999-01-26
US09/313,463 US6638727B1 (en) 1999-01-26 1999-05-17 Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
PCT/US2000/001961 WO2000042841A1 (fr) 1999-01-26 2000-01-25 Procedes d'identification, de traitement ou de controle des patients asymptomatiques, pour la reduction des risques ou le traitement therapeutique du cancer du sein

Publications (1)

Publication Number Publication Date
IL144558A0 true IL144558A0 (en) 2002-05-23

Family

ID=26815128

Family Applications (6)

Application Number Title Priority Date Filing Date
IL14440300A IL144403A0 (en) 1999-01-26 2000-01-25 Methods and devices for delivery of agents to breast milk ducts
IL14455800A IL144558A0 (en) 1999-01-26 2000-01-25 Methods for identifying, treating of monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
IL14440200A IL144402A0 (en) 1999-01-26 2000-01-25 Identifying, monitoring, and treating women for breast precancer or cancer
IL144402A IL144402A (en) 1999-01-26 2001-07-18 Identification, follow-up and treatment of women in pre-cancer or breast cancer
IL144403A IL144403A (en) 1999-01-26 2001-07-18 Devices for the transmission of causes of milk ducts in the breast
IL144558A IL144558A (en) 1999-01-26 2001-07-25 Methods for identifying treatment or monitoring of asymptomatic patients for reducing the risk of disease or for medical treatment of breast cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14440300A IL144403A0 (en) 1999-01-26 2000-01-25 Methods and devices for delivery of agents to breast milk ducts

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL14440200A IL144402A0 (en) 1999-01-26 2000-01-25 Identifying, monitoring, and treating women for breast precancer or cancer
IL144402A IL144402A (en) 1999-01-26 2001-07-18 Identification, follow-up and treatment of women in pre-cancer or breast cancer
IL144403A IL144403A (en) 1999-01-26 2001-07-18 Devices for the transmission of causes of milk ducts in the breast
IL144558A IL144558A (en) 1999-01-26 2001-07-25 Methods for identifying treatment or monitoring of asymptomatic patients for reducing the risk of disease or for medical treatment of breast cancer

Country Status (10)

Country Link
US (7) US6638727B1 (fr)
EP (3) EP1147223A4 (fr)
JP (2) JP2002535635A (fr)
AT (1) ATE335503T1 (fr)
AU (5) AU766336B2 (fr)
CA (3) CA2361123A1 (fr)
DE (1) DE60029926T2 (fr)
ES (1) ES2269103T3 (fr)
IL (6) IL144403A0 (fr)
WO (3) WO2000043038A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117439A4 (fr) * 1998-10-02 2002-11-20 Pro Duct Health Inc Methodes de reconnaissance, de diagnostic et de traitement du cancer du sein
US6413228B1 (en) * 1998-12-28 2002-07-02 Pro Duct Health, Inc. Devices, methods and systems for collecting material from a breast duct
AU2971700A (en) 1999-01-21 2000-08-07 Wayne State University Method and apparatus for measuring factors in mammary fluids
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
DE60031114T2 (de) * 1999-06-11 2007-05-03 Cytyc Corp., Marlborough Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes
US20040153001A1 (en) * 1999-12-28 2004-08-05 David Hung Devices, methods and systems for collecting material from a breast duct
EP1785727A3 (fr) * 2000-08-08 2007-08-29 Cytyc Corporation Identification d'agents viraux dans les conduits du sein et thérapie antivirale correspondante
ATE360209T1 (de) 2000-08-08 2007-05-15 Cytyc Corp Nachweis viraler agentien in brustmilchkanälen und antivirale therapie
DE10042411A1 (de) * 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
CA2445577C (fr) 2001-04-30 2012-07-03 Symbiontics, Inc. Ciblage intracellulaire de proteines therapeutiques
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6866994B2 (en) 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
JP2004532082A (ja) * 2001-05-30 2004-10-21 ネオマトリックス・エルエルシー 非侵襲性管内流体診断スクリーン
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003079906A1 (fr) * 2002-03-19 2003-10-02 Cytyc Health Corporation Methode et dispositif servant a analyer un liquide secrete par une glande mammaire
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
US6749582B2 (en) * 2002-04-30 2004-06-15 The First Years Inc. Pumping breast milk
WO2004112575A2 (fr) * 2003-06-20 2004-12-29 Amgen Inc. Amplification et surexpression geniques dans le cancer
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050208499A1 (en) * 2004-02-04 2005-09-22 Graff Jonathan M Markers for diagnosing and treating breast and ovarian cancer
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
WO2005099695A1 (fr) * 2004-04-19 2005-10-27 Novartis Ag Systemes d'administration de medicament destine a la prevention et au traitement de maladies vasculaires
EP1778874B1 (fr) 2004-07-30 2011-11-23 Adeza Biomedical Corporation Fibronectine oncofoetale en tant que marqueur de cancer du col utérin
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US7507533B2 (en) * 2004-09-24 2009-03-24 Vitrimark, Inc. Systems and methods of identifying biomarkers for subsequent screening and monitoring of diseases
EP1877775A4 (fr) * 2005-05-02 2009-06-24 Univ Missouri Detection de marqueurs biologiques carbohydrates
EP1905824A4 (fr) * 2005-05-31 2009-02-25 Olympus Corp Cellule à gène transféré et procédé d'analyse cellulaire
US20090215111A1 (en) * 2005-06-07 2009-08-27 Veenstra Timothy D Analysis of steroid hormones in thin tissue sections
US20070004045A1 (en) * 2005-06-07 2007-01-04 Xia Xu Analysis of large numbers of estrogens and other steroids and applications thereof
WO2007011708A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent a revetement polymere renfermant de la rapamycine amorphe
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
KR20090003149A (ko) * 2005-09-30 2009-01-09 안티캔서, 인코포레이티드 인간 암의 초기, 암의 진행 및 재발 마커의 동정 방법
US8137256B2 (en) 2005-12-16 2012-03-20 Portola Medical, Inc. Brachytherapy apparatus
US20070270627A1 (en) * 2005-12-16 2007-11-22 North American Scientific Brachytherapy apparatus for asymmetrical body cavities
US7862497B2 (en) 2006-04-21 2011-01-04 Portola Medical, Inc. Brachytherapy device having seed tubes with individually-settable tissue spacings
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
IL177550A0 (en) 2006-08-17 2006-12-31 Sialo Technology Israel Ltd All-in-one optical microscopic handle
WO2008039482A2 (fr) * 2006-09-26 2008-04-03 The Regents Of The University Of California Méthodes et compositions pour la prévention et le traitement du cancer
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008063511A2 (fr) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Méthodes de traitement de la maladie de pompe
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
AU2009251504B2 (en) 2008-04-17 2013-09-05 Micell Technologies, Inc. Stents having bioabsorbable layers
JP2011135904A (ja) * 2008-04-18 2011-07-14 Kowa Co 乳癌及び／又は乳腺炎治療用イオントフォレシス製剤
US20090263385A1 (en) * 2008-04-18 2009-10-22 Schulz Thadeus J Breast carcinoma treatment method
EP2279210B1 (fr) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Peptides de ciblage lysosomial et leurs utilisations
WO2011009096A1 (fr) 2009-07-16 2011-01-20 Micell Technologies, Inc. Dispositif médical distributeur de médicament
CA2730995C (fr) 2008-07-17 2016-11-22 Micell Technologies, Inc. Dispositif medical d'administration de medicament
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
WO2010083485A2 (fr) 2009-01-16 2010-07-22 Learning Curve Brands, Inc. Tire-lait et procédé d'utilisation associé
CA2756386C (fr) 2009-03-23 2019-01-15 Micell Technologies, Inc. Dispositif medical d'administration de medicament
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
CA2759015C (fr) 2009-04-17 2017-06-20 James B. Mcclain Endoprotheses vasculaires ayant une elution controlee
JP5229093B2 (ja) * 2009-04-28 2013-07-03 学校法人北里研究所 骨成長に対するエストロゲン作用の判定
EP2475376B1 (fr) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations pour enzymes lysosomales
WO2011097103A1 (fr) 2010-02-02 2011-08-11 Micell Technologies, Inc. Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose
CA2797110C (fr) 2010-04-22 2020-07-21 Micell Technologies, Inc. Endoprotheses et autres dispositifs ayant un revetement de matrice extracellulaire
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2011159769A2 (fr) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci
CA2805631C (fr) 2010-07-16 2018-07-31 Micell Technologies, Inc. Dispositif medical d'administration de medicament
EP2433644A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Traitement du cancer du sein
EP2434285A1 (fr) * 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Diagnostic du cancer du sein
WO2013012689A1 (fr) 2011-07-15 2013-01-24 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
RU2487670C1 (ru) * 2011-11-03 2013-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ диагностики патологии млечных протоков молочной железы
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
EP2971101A2 (fr) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Dosage pour biomarqueurs prédictifs
WO2014186532A1 (fr) 2013-05-15 2014-11-20 Micell Technologies, Inc. Implants biomedicaux bioabsorbables
AU2016294526A1 (en) * 2015-07-14 2018-02-08 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
WO2018063985A1 (fr) 2016-09-28 2018-04-05 Atossa Genetics Inc. Méthodes de thérapie cellulaire adoptive
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
WO2019126538A1 (fr) * 2017-12-22 2019-06-27 Atossa Genetics Inc. Méthodes intracanalaires de traitement de troubles du sein
CA3109090A1 (fr) * 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Methodes diagnostiques et therapeutiques pour le traitement du cancer du sein
US20200121605A1 (en) * 2018-10-19 2020-04-23 South Dakota Board Of Regents Methods and compositions for localized intraductal drug delivery to the breast and regional lymph nodes
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US67661A (en) 1867-08-13 Improvement in tags, oe labels
US301058A (en) 1884-06-24 Bit-brace
US122076A (en) 1871-12-19 Improvement in molds for sewer-pipes
US143359A (en) 1873-09-30 Improvement in corset-clasps
US3608540A (en) 1969-02-24 1971-09-28 St Croix Research Co Method and apparatus for aiding in the detection of breast cancer
US3786801A (en) 1969-02-24 1974-01-22 Diagnostic Inc Method and apparatus for aiding in the detection of breast cancer
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3883902A (en) * 1972-08-16 1975-05-20 Medical Eng Corp Variable volume prosthetic assembly
US4202329A (en) 1978-05-05 1980-05-13 Kortum William M Method and apparatus for inducing immunological and resistant response in mammary glands
US4365632A (en) 1978-05-05 1982-12-28 Kortum William M Method and apparatus for inducing immunological and resistant response in mammary glands
US4340054A (en) * 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4659673A (en) * 1985-11-01 1987-04-21 Brown Lewis R Replicator for cultures of microorganisms
US4838862A (en) * 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
GB9027422D0 (en) 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
GB9309966D0 (en) * 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors
US5478556A (en) 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5518885A (en) 1994-04-19 1996-05-21 The United States Of America As Represented By The Department Of Health & Human Services ERBB2 promoter binding protein in neoplastic disease
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5763415A (en) 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
WO1997005898A1 (fr) 1995-08-03 1997-02-20 The Johns Hopkins University School Of Medicine Destruction de l'epithelium d'une glande exocrine dans le traitement prophilactique et therapeutique du cancer
US5801021A (en) * 1995-10-20 1998-09-01 The Regents Of The University Of California Amplifications of chromosomal region 20q13 as a prognostic indicator in breast cancer
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6229603B1 (en) * 1997-06-02 2001-05-08 Aurora Biosciences Corporation Low background multi-well plates with greater than 864 wells for spectroscopic measurements
US6426050B1 (en) * 1997-05-16 2002-07-30 Aurora Biosciences Corporation Multi-well platforms, caddies, lids and combinations thereof
US6221622B1 (en) * 1998-04-28 2001-04-24 The Regents Of The University Of California Method and kit for obtaining fluids and cellular material from breast ducts
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample

Also Published As

Publication number Publication date
ATE335503T1 (de) 2006-09-15
US20070161063A1 (en) 2007-07-12
EP1144003B1 (fr) 2006-08-09
US6638727B1 (en) 2003-10-28
JP2002535628A (ja) 2002-10-22
WO2000042841A1 (fr) 2000-07-27
EP1144003A1 (fr) 2001-10-17
US7384418B2 (en) 2008-06-10
WO2000043553A1 (fr) 2000-07-27
CA2358971A1 (fr) 2000-07-27
AU764777B2 (en) 2003-08-28
US20030022161A1 (en) 2003-01-30
IL144402A0 (en) 2002-05-23
CA2361122A1 (fr) 2000-07-27
AU2003248031A1 (en) 2003-10-30
EP1147223A4 (fr) 2003-04-16
AU763610B2 (en) 2003-07-31
AU2632000A (en) 2000-08-07
EP1146787A4 (fr) 2003-05-07
AU2740600A (en) 2000-08-07
CA2361123A1 (fr) 2000-07-27
US20040147904A1 (en) 2004-07-29
AU766336B2 (en) 2003-10-16
IL144558A (en) 2007-03-08
WO2000043038A1 (fr) 2000-07-27
EP1146787A1 (fr) 2001-10-24
IL144402A (en) 2007-03-08
US20040091423A1 (en) 2004-05-13
DE60029926T2 (de) 2007-03-01
ES2269103T3 (es) 2007-04-01
JP2002535635A (ja) 2002-10-22
EP1147223A1 (fr) 2001-10-24
US20030021787A1 (en) 2003-01-30
AU2631900A (en) 2000-08-07
IL144403A0 (en) 2002-05-23
AU2003259578A1 (en) 2003-11-20
IL144403A (en) 2006-10-31
US20040029202A1 (en) 2004-02-12
US6642010B2 (en) 2003-11-04
EP1144003A4 (fr) 2003-05-21
DE60029926D1 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
IL144558A0 (en) Methods for identifying, treating of monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
MXPA02011099A (es) Dispositivos de suministro para tratamiento de enfermedades vasculares.
TW200722064A (en) Delivery of highly lipophilic agents via medical devices
BR0014929A (pt) Dispositivo para distribuição de medicamento, e, processo para distribuir um agente farmaceuticamente ativo para um tecido alvo dentro de um corpo
WO2007109372A3 (fr) Apport d'agents hautement lipophiles via des dispositifs médicaux
WO2007111885A3 (fr) Administration d'agents fortement lipophiles par des dispositifs médicaux
ATE288776T1 (de) Ausdehnbare vorrichtung zur behandlung von tumoren
WO2006026210A3 (fr) Dispositif d'administration d'agents au niveau d'une region tissulaire parallelement a une prevention de fuite
WO2002095352A3 (fr) Systeme de surveillance de l'observance d'un traitement
WO2005027996A3 (fr) Application d'une substance therapeutique sur une zone tissulaire au moyen d'un dispositif medical extensible
CA2350838A1 (fr) Systeme a liberation controlee pour l'administration d'agents therapeutiques a l'interieur de l'oreille interne
AU6178201A (en) Method and apparatus for diagnostic and therapeutic agent delivery
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MXPA04000934A (es) Tampon de suministro de agente terapeutico.
GB2364916B (en) Drug delivery device
WO1999055285A3 (fr) Dispositif de dilatation et de soutien renfermant des inhibiteurs de maladie, et son mode d'utilisation
EP1165160A4 (fr) Dispositif, procedes et necessaires destines a un apport simultane d'une substance dans plusieurs canaux galactophores
WO2000018331A3 (fr) Systemes d'administration de medicaments
TW200509998A (en) Controlled release of highly soluble agents
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
Henderson et al. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study
WO2009073918A3 (fr) Dispositif de délivrance d'un agent et procédé
DE602005026510D1 (en) Anthracyclinderivate
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación